The 2023 Annual report is nothing that we did not know, very...

The 2023 Annual report is nothing that we did not know, very professional as one would expect and still a few quid in the bank....

The main differance is now PAB are pushing(it seems like every other sentance)2024 for first in human clinical trials, 12 months ago every other sentance was pushing 2023.....CAN WE GET THERE?????????????????????????

Imho it looks very unlikely, take this from the report captured below

"". This audit and review process is expected to be formally completed during the first half of FY2024. Once completed, Patrys and its CDMO intend to schedule a new production run to provide GMP-grade PAT-DX1 for the planned clinical trial. The final timing of this will be determined by the availability of a production slot with the CDMO. Patrys will inform shareholders of the timing for this run once the availability of a production slot has been confirmed by its CDMO. As a result of the investigation into this manufacturing issue, Patrys is now expecting to initiate its Phase 1 first-in-human study of PAT-DX1 in 2024. The timing of starting the trial will be determined by the availability of material from the new production run and the securing of approval from the Human Research Ethics Committees (HRECs) at the clinical trial sites.

The last Ann said we would have our final report on the failed production run in the coming months and then they could work on getting back to production and then initiating trials...
Now the audit and review process is expected to be formally completed during the first half of FY2024 which could take us upto 30th June 2024......?
Only when the audit is completed can we schedule a new production run, the timing of this is determined by the availability of a production run slot with our CDMO partners.....

PAB expecting to initiate Phase 1 studies in 2024......"" The timing of starting the trial will be determined by the availability of material from the new production run and the securing of approval from the Human Research Ethics Committees (HRECs) at the clinical trial sites. "" and this is after we have had to wait for the audit to be formilised and produced....

The way i see it is we have A very long road ahead and with long timelines for even our DX3 to go for its engineering run(which imho will be paramount to licencing/partnering) and DX-1 looking very thin to get to trials next year then 6yr lows and below look almost certain.....

Buying, holding and waiting at these lows is not a bad punt at all, but as most long termers are hugely in the red it is also soooooooooooooo frustrating..

Left field Ann on a deal/partnership?, not anytime soon imo as we would have had one ages ago if we didnt have problems with production..

Not much costs this quarter, but the next one(or possibly the one after)we will need plenty, at what price?